|
|
|
Insider
Information: |
Shah Nimish P |
Relationship: |
Director |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
50,221,732 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$448,472,618 |
|
|
Total
Shares |
50,221,732 |
|
|
Total
Value |
$448,472,618 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
66
|
4
|
Stock
price went up :
|
7
|
0
|
Stock
price went down : |
59
|
4
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
Percentage
Gain/Loss : |
-52.1%
|
-384.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Bellerophon Therapeutics Inc |
BLPH |
10% Owner |
2018-08-14 |
0 |
2018-09-17 |
7,386,163 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
10% Owner |
2019-03-18 |
0 |
2024-02-08 |
4,824,731 |
Premium* |
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
|
0 |
2019-12-13 |
4,016,873 |
Premium* |
|
Altimmune, Inc |
ALT |
10% Owner |
2020-05-26 |
0 |
2021-02-25 |
3,500,000 |
Premium* |
|
Cogent Biosciences, Inc. |
COGT |
10% Owner |
2020-08-14 |
0 |
2020-08-18 |
4,355,273 |
Premium* |
|
Tricida, Inc. |
TCDA |
10% Owner |
2022-06-02 |
0 |
2022-10-26 |
3,751,406 |
Premium* |
|
Vistagen Therapeutics Inc |
VTGN |
10% Owner |
|
0 |
2022-07-12 |
20,637,286 |
Premium* |
|
Apogee Therapeutics, Inc. |
APGE |
Director |
2023-07-13 |
0 |
2023-07-13 |
1,750,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALT |
Altimmune, Inc |
10% Owner |
|
2020-05-26 |
4 |
B |
$8.79 |
$6,539,642 |
I/I |
700,000 |
2,396,364 |
1.5 |
% |
|
ALT |
Altimmune, Inc |
10% Owner |
|
2020-05-27 |
4 |
B |
$7.23 |
$3,098,761 |
I/I |
402,162 |
2,798,526 |
1.5 |
% |
|
ALT |
Altimmune, Inc |
10% Owner |
|
2020-05-28 |
4 |
B |
$7.79 |
$1,757,090 |
I/I |
201,474 |
3,000,000 |
1.5 |
% |
|
ALT |
Altimmune, Inc |
10% Owner |
|
2020-06-15 |
4 |
B |
$7.54 |
$11,310,000 |
I/I |
1,500,000 |
4,500,000 |
1.5 |
% |
|
ALT |
Altimmune, Inc |
10% Owner |
|
2021-02-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
3,500,000 |
0 |
- |
|
APGE |
Apogee Therapeutics, Inc. |
Director |
|
2023-07-13 |
4 |
B |
$17.00 |
$29,750,000 |
I/I |
1,750,000 |
1,750,000 |
2.1 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-08-14 |
4 |
B |
$0.65 |
$123,868 |
I/I |
190,977 |
6,202,770 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-08-15 |
4 |
B |
$0.65 |
$175,902 |
I/I |
272,000 |
6,474,770 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-08-16 |
4 |
B |
$0.65 |
$43,109 |
I/I |
66,393 |
6,541,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-05 |
4 |
B |
$0.85 |
$42,325 |
I/I |
50,000 |
6,591,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-06 |
4 |
B |
$0.84 |
$42,095 |
I/I |
50,000 |
6,641,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-07 |
4 |
B |
$0.90 |
$53,742 |
I/I |
60,000 |
6,701,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-10 |
4 |
B |
$1.22 |
$243,640 |
I/I |
200,000 |
6,901,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-11 |
4 |
B |
$1.14 |
$228,840 |
I/I |
200,000 |
7,101,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-12 |
4 |
B |
$1.15 |
$85,913 |
I/I |
75,000 |
7,176,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-13 |
4 |
B |
$1.19 |
$89,160 |
I/I |
75,000 |
7,251,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-14 |
4 |
B |
$1.23 |
$92,250 |
I/I |
75,000 |
7,326,163 |
1.5 |
- |
|
BLPH |
Bellerophon Therapeutics ... |
10% Owner |
|
2018-09-17 |
4 |
B |
$1.18 |
$70,944 |
I/I |
60,000 |
7,386,163 |
1.5 |
- |
|
CNST |
Constellation Pharmaceuti... |
10% Owner |
|
2019-10-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,616,873 |
|
- |
|
CNST |
Constellation Pharmaceuti... |
10% Owner |
|
2019-12-13 |
4 |
B |
$34.50 |
$13,800,000 |
I/I |
400,000 |
4,016,873 |
1.5 |
- |
|
COGT |
Cogent Biosciences, Inc. |
10% Owner |
|
2020-08-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,904,273 |
|
- |
|
COGT |
Cogent Biosciences, Inc. |
10% Owner |
|
2020-08-14 |
4 |
B |
$2.30 |
$230,000 |
I/I |
100,000 |
4,004,273 |
1.5 |
- |
|
COGT |
Cogent Biosciences, Inc. |
10% Owner |
|
2020-08-17 |
4 |
B |
$2.57 |
$642,500 |
I/I |
250,000 |
4,254,273 |
1.5 |
- |
|
COGT |
Cogent Biosciences, Inc. |
10% Owner |
|
2020-08-18 |
4 |
B |
$2.62 |
$264,620 |
I/I |
101,000 |
4,355,273 |
1.5 |
- |
|
KALV |
Kalvista Pharmaceuticals ... |
10% Owner |
|
2019-03-18 |
4 |
S |
$28.75 |
$14,375,000 |
I/I |
(500,000) |
1,544,112 |
0 |
- |
|
93 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|